Betahistine

ABSTRACT Background: Ménière’s disease (MD) is characterized by recurrent, sudden episodes of disabling vertigo. A previous randomized, controlled study demonstrated a high efficacy of a fixed combination of cinnarizine 20mg and dimenhydrinate 40mg (Arlevert®, tid.) in MD, with no statistically significant difference to betahistine (dimesylate salt, 12mg, tid). Objective: This post hoc analysis was performed […]

The aim of the study was to observe the usefulness of Betaserc in therapy of vestibular disorders in the patients with vertebro-basilar insufficiency.

The AIM of this investigation is to evaluate the effect of Betaserc – 16 and 8 mg on the patients (workers in the system of transport), with vascular auditory and vestibular disturbances.

The aim of the study was to observe the usefulness of Betaserc in therapy of vestibular disorders in the patients with vertebro-basilar insufficiency. 80 patients (43 female, 37 male) were tested on the base of videonystagmography, stabilometry and brain stem auditory evoked potentials. Betaserc was ordered in two separate doses: 3x 8mg and 3x 16 […]

The author proposes, as disease for the study of drugs activity on vestibular compensation mechanisms in man, a peripheral labyrinthine disease without spontaneous nystagmus of type II or III. He evaluates the state of compensation by the evolution of static posturography parameters and by the score of Norre’s VHT (vestibular habituation training) during an observation […]

In a randomized, double-blind clinical study, we evaluated the efficacy and tolerability of the fixed combination of cinnarizine, 20 mg, and dimenhydrinate, 40 mg (Arlevert [ARL]) in comparison to betahistine dimesylate (12 mg) in 82 patients suffering from Ménière’s disease for at least 3 months and showing the characteristic triad of symptoms (paroxysmal vertigo attacks, […]